PURPLE BIOTECH LTD.
PPBT evidence brief
What we can confirm
- Market Cap:
- $2.9M
What it means
What to watch
Prepared research question
What matters most for PPBT—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · PPBT
Purple Biotech Ltd. is a clinical-stage biotechnology company developing a next-generation immunotherapy platform of masked tri-specific antibodies to treat cancer.
Key risk: Need for substantial additional capital
Market Cap
$2.9M
Cash Runway
—
Lead Asset
—
Next Catalyst
—
Financial data as of Dec 31, 2025.
Purple Biotech Ltd. is a clinical-stage biotechnology company developing a next-generation immunotherapy platform of masked tri-specific antibodies to treat cancer.
- Purple Biotech is a clinical-stage company developing a next-generation immunotherapy platform, CAPTN-3, which includes masked tri-specific antibodies designed to maximize anti-cancer potency while minimizing toxicity [sec · filed 2026-03-19].
- The lead candidate from the CAPTN-3 platform, IM1240, is advancing toward the clinic, and a second candidate, IM1305, is in preclinical development [sec · filed 2026-03-19].
- As of December 31, 2025, the company had cash and short-term investments of $8.7M and shareholders' equity of $9.7M, but reported an accumulated deficit of $171 million [sec · filed 2026-03-19].
- The company's pipeline also includes clinical-stage assets CM24 and NT219, though key focus is on the CAPTN-3 platform [sec · filed 2026-03-19].
- The company's long-term capital requirements depend on its ability to raise additional funds and/or successfully out-license or commercialize its therapeutic candidates, as existing cash is not sufficient to complete all current development programs [sec · filed 2026-03-19].
What works
- The CAPTN-3 platform uses masking technology to confine immune activation to the tumor microenvironment, potentially expanding the therapeutic window versus unmasked T-cell engagers [sec · filed 2026-03-19].
- The platform engages both T cells and NK cells simultaneously, which may offer a differentiated mechanism for anti-tumor activity [sec · filed 2026-03-19].
- The company has a defined strategy to focus on oncology therapeutics for unmet medical needs with significant market opportunities [sec · filed 2026-03-19].
- The lead candidate IM1240 is advancing toward the clinic, representing a near-term value inflection point [sec · filed 2026-03-19].
What to weigh
- The company acknowledges it will need substantial additional funds to complete development and commercialization, and financing may not be available on acceptable terms [sec · filed 2026-03-19].
- As of December 31, 2025, the company had an accumulated deficit of $171 million and expects to continue incurring significant losses, with no near-term profitability [sec · filed 2026-03-19].
- The company's therapeutic candidates represent novel approaches, creating substantial uncertainties regarding development timelines, regulatory approval, market acceptance, and reimbursement [sec · filed 2026-03-19].
- If collaborations or out-licensing fail to deliver on schedule, development and revenue generation will be materially delayed or harmed [sec · filed 2026-03-19].
From the filings
Quoted directly from source documents.
Company is clinical-stage, focused on masked tri-specific antibody platform.
“We are a clinical-stage company developing a next-generation immunotherapy platform designed to maximize anti-cancer potency while minimizing toxicity. We are focused on advancing our lead program, CAPTN-3 - a platform of masked tri-specific antibodies that simultaneously target tumors while engaging both T cells and NK cells.”
SEC filings · March 19, 2026
Accumulated deficit as of December 31, 2025.
“As of December 31, 2025, we had an accumulated deficit of $171 million.”
SEC filings · March 19, 2026
Cash will not be sufficient to complete development without additional funds.
“cash and short-term investments are not sufficient to complete the research and development of our therapeutic candidates in their current phase of development and any additional therapeutic candidates that we may acquire, in-license or develop in the future, and to fund our related expenses.”
SEC filings · March 19, 2026
Risk of relying on collaborations for clinical development.
“If such collaboration fails to perform as expected, our clinical trials and/or development plans will be delayed, and we will be required to seek other partners, which we may not be able to engage in a timely manner, if at all, and which may delay our development plans and therefore the potential for us to generate future revenue from our therapeutic candidates would be significantly reduced and our business would be significantly harmed.”
SEC filings · March 19, 2026
Risks & what to watch (4)›
Key risks
- Need for substantial additional capital — Existing cash not sufficient for R&D; future financing may not be available on acceptable terms [sec · filed 2026-03-19].
- Reliance on novel, unproven technology — Each therapeutic candidate represents a novel approach with high uncertainty in development, approval, and market acceptance [sec · filed 2026-03-19].
- Dependence on collaboration partners — If collaborations fail to perform, development delays and revenue potential will be significantly harmed [sec · filed 2026-03-19].
- History of operating losses and accumulated deficit — $171M accumulated deficit as of 2025-12-31; expects continued losses with no near-term profitability [sec · filed 2026-03-19].
What to watch
- Progress of IM1240 advancing toward the clinic and IM1305 in preclinical development [sec · filed 2026-03-19].
- The company's ability to secure additional financing or collaborations to support continued operations [sec · filed 2026-03-19].
- Clinical data from ongoing or planned studies with CM24 and NT219, if any [sec · filed 2026-03-19].
Sources: SEC filings · Generated September 12, 2026 · How we verify sources →
Run PURPLE BIOTECH LTD. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available PURPLE BIOTECH LTD. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Financials
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
15
Total value held
$306K
| Holder | Shares | Value |
|---|---|---|
| susquehanna international group, llp | 53,403 | $216K |
| smartharvest portfolios, llc | 18,127 | $73K |
| bnp paribas financial markets | 1,957 | $8K |
| rhumbline advisers | 710 | $3K |
| simplex trading, llc | 597 | $2K |
| morgan stanley | 578 | $2K |
| gamma investing llc | 108 | $436 |
| ubs group ag | 99 | $400 |
| sbi securities co., ltd. | 31 | $125 |
| group one trading llc | 20 | $81 |
Showing top 10 of 15 institutional holders of PURPLE BIOTECH LTD.. Open the full 13F history after sign-in.
Short Interest
as of May 22, 2026- % of float
- 1.1%
- Days to cover
- 0.8
- Shares short
- 10,481
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
PPBT short interestFrequently asked questions
What is the AI investment thesis for PURPLE BIOTECH LTD.?
Purple Biotech Ltd. is a clinical-stage biotechnology company developing a next-generation immunotherapy platform of masked tri-specific antibodies to treat cancer.
Who is the CEO of PURPLE BIOTECH LTD.?
Mr. Gil Efron CPA, M.A. is the chief executive officer of PURPLE BIOTECH LTD. (PPBT).
Where is PURPLE BIOTECH LTD. headquartered?
PURPLE BIOTECH LTD. (PPBT) is headquartered in Rehovot, Israel.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.